ReviewThe Medical clinics of North America2019
Proton Pump Inhibitor-Refractory Gastroesophageal Reflux Disease.
Review in The Medical clinics of North America, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 40 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
40 citing papers in PubMed, 1 synthesis or guideline pooled it, 100 citations in OpenAlex.
- Efficacy of Baclofen as Add-on Therapy for Refractory Gastroesophageal Reflux Disease: A Meta-analysis.Journal of clinical gastroenterology · 2025Pooled it
- Mid-esophageal mucosal impedance reflects mucosal integrity and phenotypes refractory reflux-like symptoms.BMC gastroenterology · 2026Article
- The pathogenesis and surgical treatment progress of gastroesophageal reflux disease.Frontiers in surgery · 2026Review
- Vietnam Association of Gastroenterology (VNAGE) guideline on the management of gastroesophageal reflux disease.Frontiers in medicine · 2026Review
- Systematic analysis of proton pump inhibitors-related adverse reactions using the FDA adverse event reporting system database.PloS one · 2026Article
- Expert recommendations for the management of refractory gastroesophageal reflux disease in systemic sclerosis: A report from the World Scleroderma Foundation (WSF) Gastrointestinal "Ad hoc committee".Journal of scleroderma and related disorders · 2026Article
- Amprenavir Mitigates Pepsin-Induced Transcriptomic Changes in Normal and Precancerous Esophageal Cells.International journal of molecular sciences · 2025Article
- American Society for Gastrointestinal Endoscopy guideline on the diagnosis and management of GERD: methodology and review of evidence.VideoGIE : an official video journal of the American Society for Gastrointestinal Endoscopy · 2025Article
- Efficacy and safety of proton pump inhibitors for diabetes mellitus in patients with gastroesophageal reflux disease: a meta-analysis.Archives of medical science : AMS · 2025Review
- Correlation between the type of esophagogastric junction and refractory reflux esophagitis.International journal of clinical and experimental pathology · 2025Article
- Multidimensional mechanisms and therapies underlying gastroesophageal reflux disease: focus on immunity, signaling pathways, and the microbiota-gut-brain axis.Frontiers in immunology · 2025Review
- Multicentric short term and safety study of ineffective esophageal motility patients treated with RefluxStop device.Scientific reports · 2024Observational
- Implementing pharmacogenetic testing to optimize proton-pump inhibitors use among Indian population based on CPIC-CYP2C19-PPI dosing guidelines: The need of the hour.Indian journal of pharmacology · 2024Review
- Socioeconomic traits and the risk of Barrett's esophagus and gastroesophageal reflux disease: A Mendelian randomization study.World journal of gastrointestinal oncology · 2024Article
- Potential drug targets for gastroesophageal reflux disease and Barrett's esophagus identified through Mendelian randomization analysis.Journal of human genetics · 2024Article
- Chinese expert consensus on diagnosis and management of gastroesophageal reflux disease in the elderly (2023).Aging medicine (Milton (N.S.W)) · 2024Article
- A systematic review with meta-analysis: Efficacy and safety of potassium-competitive acid blocker compared with proton pump inhibitor in the maintenance of healed erosive esophagitis.JGH open : an open access journal of gastroenterology and hepatology · 2024Review
- Article
- Updates in the Management of Erosive Esophagitis.The Journal of family practice · 2023Article
- Approach to Management of Refractory Gastroesophageal Reflux Disease.Gastroenterology & hepatology · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
Proton pump inhibitor (PPI)-refractory gastroesophageal reflux disease (GERD) is defined by the presence of troublesome GERD symptoms despite PPI optimization for at least 8 weeks in the setting of ongoing documented pathologic gastroesophageal reflux. It arises from a dysfunction in protective systems to prevent reflux and as propagation of physiologic reflux events. Treatment possibilities include pharmacologic options, invasive management strategies, and endoluminal therapies. Management strategy should be personalized to the patient's needs and mechanistic dysfunction. This article reviews the definition, mechanisms, and management options for PPI-refractory GERD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.